Galectin Therapeutics Inc. (GALT) — Stock Score Summary

Galectin Therapeutics Inc. (GALT) has a MoatMap StockRank of 1/100 based on Quality (23/100), Value (36/100), and Momentum (8/100) factor scores. The current signal is STRONG SELL. Galectin Therapeutics is a clinical-stage biotech with no commercialized products and negative cash flows. It does not benefit from the CDMO pricing power cycle as it is a drug developer rather than a manufacturer, failing our quality and cash flow requirements.

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the research and development of therapies for fibrotic liver diseases and cancer. The company's competitive moat is centered on its proprietary galectin-3 inhibitor, belapectin, which is designed to target the root causes of NASH cirrhosis and enhance cancer immunotherapies. It operates as a highly specialized biotechnology player addressing complex, high-value medical indications with significant unmet needs.

Key Financial Metrics

Price$2.41
Market Cap$169M
P/E (Forward)-1.42
Price/Book-1.18
Return on Invested Capital-204.4%
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-19M

Galectin Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Galectin Therapeutics Inc.’s (GALT) StockRank?
MoatMap’s StockRank for Galectin Therapeutics Inc. (GALT) is 1/100, with a Strong Sell signal. It is a composite of Quality (23), Value (36), and Momentum (8) factor ranks across MoatMap’s 19,000+ stock universe.
Does Galectin Therapeutics Inc. have an economic moat?
Galectin Therapeutics Inc. (GALT) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Galectin Therapeutics Inc. a buy, hold, or sell?
MoatMap’s current signal for Galectin Therapeutics Inc. (GALT) is Strong Sell, based on a StockRank of 1/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Galectin Therapeutics Inc. in?
Galectin Therapeutics Inc. (GALT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksGALT deep dive reportAI ChampionsHow we score stocksSense-check another stock